Fund manager Candriam has added to its healthcare range with the launch of a fund targeting stocks in global sub-sectors such as pharmaceuticals and biotechnology.
The fund seeks to capitalise on the high growth potential of the healthcare sector driven by demographic trends, innovation, and developments in emerging markets.
The Candriam Equities L Life Care fund will be managed by Rudi Van den Eynde, head of thematic global equity, and Servaas Michielssens, a senior biotechnology analyst at the firm.
Van den Eynde, lead portfolio manager, said it was an exciting time to be launching the fund due to the broad progress seen in medical technologies in general.
The investment universe consists of quoted companies that are active in the broad healthcare space, including pharmaceuticals, biotechnology, life sciences, healthcare equipment and technology, with a market cap of more than $250 million (€210.5 million).
The actively-managed fund is said to draw on research and clinical data rooted in over 20 years of biotechnology expertise.
It is the latest addition to the firm’s healthcare strategy which was launched in 1997.
© 2021 funds europe